(NASDAQ:BDSI) to report earnings per share of ($0.23) for the current fiscal quarter, according to Zacks Investment Research. After having $0.28 EPS previously, Cross Timbers Royalty Trust's analysts see 0.00% EPS growth.
08/10/2016 - BioDelivery Sciences International, Inc. had its "overweight" rating reiterated by analysts at Piper Jaffray. The business is expected to announce its next earnings results on Wednesday, November 8th. A month ago, analyst EPS consensus estimated earnings of US$-0.23 per share. Price T Rowe Assocs Md stated it has 0% of its portfolio in BioDelivery Sciences International, Inc. Below is a list of BioDelivery Sciences International, Inc.
05/30/2014 - BioDelivery Sciences International, Inc. was downgraded to "sell" by analysts at ING. The company had revenue of $8.70 million during the quarter, compared to analysts' expectations of $8.45 million. During the same period in the previous year, the company earned ($0.31) EPS. The company's quarterly revenue was up 74.0% on a year-over-year basis. (NASDAQ:BDSI) for 17,200 shares. Hikari Power Ltd acquired 336,675 shares as Biodelivery Sciences International Inc (BDSI)'s stock rose 30.67%. (NASDAQ:BDSI). Driehaus Cap Mgmt owns 0.01% invested in BioDelivery Sciences International, Inc. HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a report on Friday, June 23rd. (NASDAQ:BDSI). New York-based Hrt Ltd Liability Company has invested 0.08% in BioDelivery Sciences International, Inc. The company has a consensus rating of "Buy" and a consensus target price of $4.21. The firm has "Buy" rating by Piper Jaffray given on Wednesday, August 9.
07/24/2017 - BioDelivery Sciences International, Inc. had its "buy" rating reiterated by analysts at Janney Montgomery Scott. The firm has "Market Perform" rating by FBR Capital given on Friday, August 5. Ameriprise invested in 0% or 1.90M shares. Sterling invested 0.18% in BioDelivery Sciences International, Inc.
About 2.00M shares traded. Goodnow Investment Group Llc sold 329,841 shares as Aircastle Ltd (AYR)'s stock declined 9.97%.
The stock's 50 day moving average is 2.96 and its 200 day moving average is 2.57. BioDelivery Sciences International, Inc. has a 52-week low of 1.50 and a 52-week high of 3.60. The company has market cap of $160.88 million. The total value of its holdings increased 234.8%. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The shares were sold at an average price of $2.75, for a total value of $67,419.00. The disclosure for this sale can be found here. Insiders sold a total of 402,127 shares of company stock worth $1,142,798 over the last ninety days. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company.
Goodnow Investment Group Llc increased Genesee & Wyo Inc (NYSE:GWR) stake by 78,340 shares to 566,967 valued at $38.78 million in 2017Q2. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company's stock worth $126,000 after purchasing an additional 13,341 shares in the last quarter. Stonepine Capital Management, LLC expanded its holdings by buying 632,853 shares an increase of 22.2%. 267.53 million shares or 3.16% more from 259.34 million shares in 2017Q1 were reported.
About BioDelivery Sciences International, Inc. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company's stock valued at $210,000 after purchasing an additional 91,297 shares in the last quarter. Grandeur Peak Global Advisors LLC boosted its position in shares of BioDelivery Sciences International by 5.9% in the first quarter.
Earlier today, the company settled its patent challenge with BioDelivery Sciences related to pain med BUNAVAIL but that should not have moved the needle much. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies.